Quote:

---

The theory is that with with primarys' leronlimab, might have more value as a supplement to chemo--which is usually economical and generic--while reducing and/or preventing mets that usually cause patient mortality (with the exception of GBM).

---

Tumors flip the tumor microenvironment to their survival advantage by increasing M2 macrophages that protect them from killer M1 macrophages and decrease M1 macrophages that would kill the tumor cells. Leronlimab reverses that allowing the immune system to do it's job. It also lowers angiogenesis by downregulation of VEGF hampering the tumors ability to grow. It downregulates IL-4, IL-13, PD1/PD-L1 and other tumor protectants. All that besides stopping metastasis via CCL5 blockade. It's role in combination with chemotherapy or radiation is to hinder DNA repair of cells damaged by them but leronlimab will help kill off primary tumor cells on it's own.

I would certainly like to see how that GBM study was done and the results to try to figure out why leronlimab wasn't working.